The success rate of ITI has been demonstrated to range between 60% and 80% in patients with severe haemophilia A,11, 18, 19 although when analysed on an intent‐to‐treat basis, the success rate appears to be lower.11 When a patient is not responding to a first ITI regimen, a change in regimen (eg, dose escalation) or a change in FVIII product and/or the addition of an immunosuppressant (eg, rituximab) has been considered appropriate. Here, F8 is linked to hemophilia A.